Evaluation of Wysa Therapeutics V1.0
Research type
Research Study
Full title
Benefits of adopting WYSA therapeutics for patients, clinicians, services and the wider health care system.
IRAS ID
320441
Contact name
Lila Varsani
Contact email
Sponsor organisation
Wysa Limited
ISRCTN Number
ISRCTN10327977
Duration of Study in the UK
0 years, 6 months, 1 days
Research summary
Title: Benefits of adopting WYSA therapeutics for patients, clinicians, services and the wider health care system.
Short title: An evaluation of Wysa therapeutics.
The study proposed is a real world quantitative evaluation to investigate the impact of Wysa therapeutics on clinical outcomes, and the experience of using the products in people with mild to moderate common mental health disorders. Outcome measures will include PHQ9 and GAD7 scores, as well as clinical and/or administrative time savings.
Participants: The target population of the study will include individuals over the age of 16 years who are referred, or self-refer, to Improving Access to Psychological Therapies programme (IAPT) for mental health support
The planned sample size is 100 individuals from five provider sites, two run by Dorset University Healthcare NHS Foundation Trust and three run by East London NHS Foundation Trust.
The study will last nine months which includes three months of evaluation refinement, ethical approval, technical integration and testing. A further one month will be required for analysis of some secondary outcomes and preparation for dissemination
The main research question is: How do the range of Wysa therapeutic tools benefit patients, clinicians, services and the wider health care system?
Research Questions/ Aims: The study aims are as follows:
1. To establish real-world evidence of the effectiveness of Wysa as a referral and triage tool.
2. To establish the impact of Wysa as a self help mental health support tool for patients waiting for treatment.
3. To establish the effectiveness of therapist enabled Wysa interventions on mental health outcomes.
4. To evaluate user experience of the range of Wysa therapeutics.
5. To establish if the adoption of Wysa therapeutics results in any service related efficiencies, for example clinical or administrative time savings.REC name
London - Central Research Ethics Committee
REC reference
23/LO/0072
Date of REC Opinion
24 Feb 2023
REC opinion
Further Information Favourable Opinion